DVA vs PACS
DaVita and PACS Group, Inc., both Healthcare
DaVita is the larger company at $12B against $7.1B. On trailing earnings DVA is the cheaper of the two at a P/E of 14.9 against 26.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year PACS returned +238% against +38% for DVA. The RyuScore puts DVA ahead, 72 against 56 out of 100.
| Figure | DVA | PACS |
|---|---|---|
| Last close | $181 | $44.97 |
| Market cap | $12B | $7.1B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 14.9 | 26.3 |
| 1-year return | +38% | +238% |
| 5-year return | +55% | n/a |
| RyuScoresector-relative, 1–10 | 72/100 | 56/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
DaVita
Revenue of $3.6B in Q2 2026, net income $265M. Its largest reported line is U.S.Dialysis With Intersegment, 56% of the disclosed total.
PACS Group, Inc.
Revenue of $1.4B in Q2 2026, net income $76M.
Open these two in the interactive comparison to add more names, change the period or see the correlation.